Navidea Biopharmaceuticals (NYSE:NAVB) Earns Sell Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB) in a report issued on Monday. The brokerage set a “sell” rating on the stock.

Navidea Biopharmaceuticals Trading Up 59,900.0 %

NYSE NAVB opened at $0.06 on Monday. The stock has a fifty day simple moving average of $0.03 and a 200-day simple moving average of $0.05. Navidea Biopharmaceuticals has a twelve month low of $0.00 and a twelve month high of $0.15.

About Navidea Biopharmaceuticals

Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases.